Key result
Cancer therapies, particularly anthracyclines, pose a significant risk for delayed-onset cardiovascular disease and congestive heart failure, necessitating improved screening and management strategies.
Population
Patients receiving cancer therapies, including anthracyclines, radiation therapy, and therapies targeting…
Design
Review
Authors
Loading...
May prompt closer surveillance in anthracycline survivors; leaves optimal screening protocols open pending prospective data.
This review highlights the risks of chemotherapy-induced cardiotoxicity, particularly from anthracyclines, and emphasizes the importance of screening and early intervention to prevent congestive heart failure in cancer survivors.
Anderson et al. (2008) conducted a review in Cancer therapy-induced cardiotoxicity. Cancer therapies was evaluated. Cancer therapies, particularly anthracyclines, pose a significant risk for delayed-onset cardiovascular disease and congestive heart failure, necessitating improved screening and management strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: